DelveInsight’s, “Atypical Teratoid Rhabdoid Tumors (ATRT) – Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Atypical Teratoid Rhabdoid Tumors (ATRT) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Atypical Teratoid Rhabdoid Tumors (ATRT): Overview
An atypical teratoid rhabdoid tumor (ATRT) is a very rare, aggressive tumor of the central nervous system, occurring mostly in the cerebellum, the part of the brain that controls movement and balance, or the brain stem, the part of the brain that controls basic body functions. ATRTs usually occur by age 3, but sometimes are found in older children. ATRTs represent only 1 to 2 percent of childhood brain tumors. These tumors are part of a larger group of malignant tumors called rhabdoid tumors, which also can occur outside the brain. ATRTs may be localized to one part of the brain, or they can spread to other locations in the brain, spine or body. Most ATRTs are caused by changes in a gene known as SMARCB1 (also called INI1). This gene normally signals proteins to stop tumor growth. But in ATRTs, SMARCB1 doesn’t function properly and tumor growth is uncontrolled. The signs and symptoms of atypical teratoid rhabdoid tumor varies with patient to patient and depend on the child's age as well as tumor location. A diagnosis of typical Teratoid Rhabdoid Tumors (ATRT) is based upon a thorough clinical evaluation, and a variety of specialized tests. ATRT is most commonly diagnosed from imaging studies like Magnetic resonance imaging (MRI), Computerized tomography scan, Lumbar puncture, Ultrasound, and biopsy. Treatment of ATRT mainly includes surgery, chemotherapy or radiation therapy. Combinatorial treatment of surgical resection, chemotherapy, and radiation therapy is widely used. Multiple clinical trials testing molecularly targeted therapies are underway.
"Atypical Teratoid Rhabdoid Tumors (ATRT) - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Atypical Teratoid Rhabdoid Tumors (ATRT) pipeline landscape is provided which includes the disease overview and Atypical Teratoid Rhabdoid Tumors (ATRT) treatment guidelines. The assessment part of the report embraces, in depth Atypical Teratoid Rhabdoid Tumors (ATRT) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Atypical Teratoid Rhabdoid Tumors (ATRT) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Atypical Teratoid Rhabdoid Tumors (ATRT) R&D. The therapies under development are focused on novel approaches to treat/improve Atypical Teratoid Rhabdoid Tumors (ATRT).
This segment of the Atypical Teratoid Rhabdoid Tumors (ATRT) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Atypical Teratoid Rhabdoid Tumors (ATRT) Emerging Drugs
Tazemetostat: Epizyme
Tazemetostat is an orally administered, first-in-class small molecule EZH2 inhibitor, for the treatment of multiple types of hematological malignancies and genetically defined solid tumors. In early clinical development, tazemetostat has demonstrated clinical activity and a generally well-tolerated safety profile in both patients with hematological malignancies and genetically defined solid tumors. Epizyme is investigating tazemetostat for Atypical Teratoid Rhabdoid Tumors (ATRT) and is currently in phase II stage of development.
Alisertib: Takeda
Alisertib selectively binds to and inhibits Aurora A kinase in cells. Inhibition of Aurora A results in delayed mitotic entry and progression through mitosis leading to an accumulation of cells with a tetraploid DNA content. The drug is being evaluated either alone or in combination with other chemotherapy agents in Phase II clinical trial to treat patients with Atypical Teratoid Rhabdoid Tumors (ATRT).
Further product details are provided in the report……..
This segment of the report provides insights about the different Atypical Teratoid Rhabdoid Tumors (ATRT) drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 10+ key companies which are developing the therapies for Atypical Teratoid Rhabdoid Tumors (ATRT). The companies which have their Atypical Teratoid Rhabdoid Tumors (ATRT) drug candidates in the most advanced stage, i.e. Phase II include, Epizyme.
DelveInsight’s report covers around 10+ products under different phases of clinical development like
Atypical Teratoid Rhabdoid Tumors (ATRT) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Atypical Teratoid Rhabdoid Tumors (ATRT) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Atypical Teratoid Rhabdoid Tumors (ATRT) drugs.
Current Treatment Scenario and Emerging Therapies:
Introduction
Executive Summary
Atypical Teratoid Rhabdoid Tumors (ATRT): Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
Drug Name: Company Name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Tazemetostat: Epizyme
Drug profiles in the detailed report…..
Early stage products (Phase I)
ONC206: Chimerix
Drug profiles in the detailed report…..
Inactive Products
Atypical Teratoid Rhabdoid Tumors (ATRT) Key Companies
Atypical Teratoid Rhabdoid Tumors (ATRT) Key Products
Atypical Teratoid Rhabdoid Tumors (ATRT)- Unmet Needs
Atypical Teratoid Rhabdoid Tumors (ATRT)- Market Drivers and Barriers
Atypical Teratoid Rhabdoid Tumors (ATRT)- Future Perspectives and Conclusion
Atypical Teratoid Rhabdoid Tumors (ATRT) Analyst Views
Atypical Teratoid Rhabdoid Tumors (ATRT) Key Companies
Appendix
List of Table
Table 1: Total Products for Atypical Teratoid Rhabdoid Tumors (ATRT)
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Atypical Teratoid Rhabdoid Tumors (ATRT)
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Takeda
• Secura Bio
• Epizyme
• Vyriad, Inc.
• Chimerix
• Istari Oncology
• Novartis
• Pfizer
• DNAtrix
